Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of N-acyl-alpha amino acids. It has been studied as an experimental agent and is not approved for clinical use. The molecule features a pyrrolidine core substituted with a tert-butylbenzoyl group at position 1, an isobutyl group at position 2, and a thiazol group at position 5. Its primary mechanism of action appears to be as an inhibitor of RNA-directed RNA polymerase (NS5b), which is essential for the replication of certain viruses such as hepatitis C virus[6][10]. There are no known approved indications or marketed products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S,4S,5R)-1-(4-tert-butylbenzoyl)-2-isobutyl-5-(1,3-thiazol-2-yl)pyrrolidine-2,4-dicarboxylic acid.